CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

-Regulatory submissions complete for exagamglogene autotemcel , formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia and severe sickle cell disease - -EU and U.K.... | May 8, 2023

Related Keywords

United States ,Switzerland ,San Francisco ,California ,London ,City Of ,United Kingdom ,Massachusetts ,Boston ,American ,Susan Kim ,Samarth Kulkarni ,Raju Prasad ,Brad Bolzon ,Rachel Eides ,Exchange Commission ,Drug Administration ,Globenewswire Inc ,European Medicines Agency ,American Association For Cancer Research ,Regulatory Agency ,Viacyte Inc ,William Blair Company ,Vertex Pharmaceuticals ,Therapeutics Inc ,European Commission ,Senior Equity Research Analyst ,European Union ,Nasdaq ,Medicines Agency ,Innovation Passport ,Access Pathway ,Chief Executive Officer ,Priority Review ,Fast Track ,Regenerative Medicine Advanced Therapy ,Orphan Drug ,Rare Pediatric Disease ,Marketing Authorization Applications ,Priority Medicines ,Investigational New Drug ,New Drugs ,Horizon Session ,Cancer Research ,Chief Financial ,Managing Director ,New England Journal ,Orphan Drug Designation ,Mycosis Fungoides ,Private Securities Litigation Reform Act ,Consolidated Statements ,Crispr Therapeutics Ag Stock Exchange ,News ,Information ,Press Release ,Submissions ,Omplete ,Or ,Xagamglogene ,Utotemcel ,Formerly ,Nown ,Us ,N ,The ,Meta ,Thalassemia ,End ,Evere ,Pickle ,Fell ,Disease ,Nd Crsp Ch0334081137 ,